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Introduction
Our intended pun implies that we have reached a cross-
roads in high-dose chemotherapy for breast cancer. Is
high-dose chemotherapy going anywhere, or should we
allow it to wither on the vine? The conclusion of this com-
mentary is that, in its present form, high-dose treatment
has not been found to be superior to conventional-dose
treatment in either the metastatic or adjuvant setting.
However, we should be careful not to ‘throw the baby out
with the bath water’. Rather, we should look seriously at
intensifying chemotherapy with more active drugs, given in
different schedules. Our judgement is that using conven-
tional cytotoxic chemotherapy, the approach pioneered by
the Memorial Sloan-Kettering Hospital, New York, USA,
with ‘dose-dense’ chemotherapy given in a ‘block sched-
ule’, is likely to produce the best results [1]. However,
there is also now much to be gained from looking at bio-
logical agents in combination with conventional
chemotherapy, particularly with the recent encouraging
results with the use of trastuzumab (Herceptin, Genen-
tech, San Francisco, CA, USA) [2].
High-dose chemotherapy in breast cancer has been a
controversial issue for some time. Several phase 2 trials
showed promising results in patients with chemotherapy-
responsive metastatic disease, when the data were com-
pared with the outcome in historical control individuals
[3,4]. However, most recently published randomized trials
demonstrate a lack of effectiveness in both the adjuvant
and metastatic settings [5–8]. The trials of Bezwoda and
coworkers from South Africa [9–12] remained the only
important positive evidence for high-dose chemotherapy,
until the publication of the onsite review of the Bezwoda
studies [13] and the investigator’s admission of serious
scientific misconduct. Although international commenta-
tors [14,15] have suggested that further trials of high-
dose chemotherapy should be carried out, our view is that
such studies will have to be innovative enough to per-
suade oncological clinical investigators worldwide that
this approach is worth investigating further.
The concept of dose intensity is based on the hypothesis
that a single or tandem exposure to very high doses of
chemotherapy will eliminate any remaining tumour cells,
and thereby result in a cure. High-dose treatment is based
on escalating the dose of chemotherapeutic agents, in par-
ticular alkylating agents, which will result in severe bone
marrow depression. The technique of autologous bone
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marrow transplantation and more recently the use of
peripheral blood stem cells to restore marrow function
have made this approach possible.
There is considerable in vivo evidence that dose intensifi-
cation can improve responses in breast cancer. One of
the first studies was performed by Bonadonna et al [16].
Those investigators analyzed two of their clinical trials ret-
rospectively, and reported that patients who received a
higher percentage of the intended dose of chemotherapy
had a significantly longer disease-free survival. Review of
patients in adjuvant and palliative breast cancer trials
[17,18] suggested a linear dose–response relationship for
patients receiving conventional doses of chemotherapy.
This was particularly steep once the threshold intensity
had been surpassed. A prospective study by the Cancer
and Leukemia Group B [19] confirmed that both pre-
menopausal and postmenopausal women receiving high
or moderate doses of cyclophosphamide, doxorubicin and
fluorouracil had significantly better disease-free and
overall survival than those receiving low doses. A meta-
analysis of 14 studies with higher doses without bone
marrow support in metastatic breast cancer showed a sur-
vival advantage, although this was modest [20].
In the 1980s, high-dose treatment with bone marrow
support was introduced into breast cancer treatment after
it had proven successful in more chemosensitive diseases
such as leukaemia and lymphoma. Disappointingly, four
studies [5–8], including more than 1400 patients receiv-
ing adjuvant treatment, failed to prove an advantage in the
adjuvant setting. Similarly, there was no survival benefit in
patients with metastatic disease, although a higher
response rate was reported [21,22].
A variety of reasons potentially account for this. One
hypothesis is that the dose–response curve usually has a
sigmoid shape with a threshold, a lag phase, a linear
phase and a plateau phase [23]. The dose–response
curve is steep in the linear phase. Reduction of dose
intensity in the linear phase results in a marked decrease
in cure rates before a significant reduction in the complete
remission rate. On average, a dose reduction of 20%
leads to a loss of 50% in the cure rate. Increasing the
dose intensity can therefore be a useful way to increase
the effect of certain drugs. This potentially explains the
benefit of more dose intense, conventional regimens, as
found by Bonadonna et al [16] and Wood et al [19]. In
contrast to other malignancies such as lymphoma, the
dose–response curve for breast cancer seems to be
shifted to the left, and escalating doses to the levels used
for the high-dose treatment may reach the plateau phase.
Intrinsic resistance to the available chemotherapeutic
drugs and the development of resistant clones during
chemotherapy are also likely to be partly responsible for
the failure of high-dose chemotherapy to impact on the
survival of breast cancer patients. Some years ago Goldie
and Coldman developed a mathematical model that pre-
dicted that mutations causing drug resistance occur in
tumours of 103–106 tumour cells [24], which is much
lower than the clinically detectable level (ie a tumour at
detectable level would be almost certain to have at least
one drug-resistant clone, if not more).
Another reason for the failure of high-dose treatment in
breast cancer is the choice of drugs available for dose
escalation. The drug combinations used include mostly
alkylating agents and platinum. Unfortunately, some of the
most effective drugs in breast cancer, namely anthracy-
clines and taxanes, are not suitable for dose escalation to
the same extent because of the cardiotoxicity of anthracy-
clines and neurotoxicity of taxanes.
Conclusions
Perhaps with the resounding failure of conventional high-
dose chemotherapy approaches in breast cancer, we
should turn our attention to the ‘dose-dense’ approach
with the block scheduling suggested by the mathematical
models of Day [23], and developed clinically by Norton
and Day [1]. Our expectation of high-dose treatment with
bone marrow support has thus far not been fulfilled either
in the adjuvant or in the metastatic setting. A dose-intense
conventional approach remains the ‘gold standard’.
Although there is a variety of treatment options available,
further research is needed to explore different ways to find
improved treatment strategies. The recent introduction of
Herceptin, a cerbB2 antibody, into the clinic, which has
been shown to improve survival in patients with metastatic
disease, is one step in that direction.
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